Breaking News Instant updates and real-time market news.

MRK

Merck

$79.84

0.9 (1.14%)

, PFE

Pfizer

$42.41

0.45 (1.07%)

12:48
02/17/19
02/17
12:48
02/17/19
12:48

Merck presents results from Phase 3 KEYNOTE-426 study

Merck (MRK) announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with Pfizer's (PFE) Inlyta, a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma at the 2019 Genitourinary Cancers Symposium. This is the first combination regimen to significantly improve overall survival, progression-free survival and objective response rate compared to sunitinib. Results were consistent across all IMDC subgroups, including favorable, intermediate and poor risk groups, and regardless of PD-L1 expression. As previously announced, the U.S. Food and Drug Administration has granted priority review for a supplemental Biologics License Application for KEYTRUDA in combination with axitinib for the first-line treatment of patients with advanced RCC based on the results of KEYNOTE-426, and has set a Prescription Drug User Fee Act, or target action, date of June 20, 2019. Findings from the first interim analysis showed KEYTRUDA in combination with axitinib reduced the risk of death by 47% - significantly improving OS compared to sunitinib. For the dual primary endpoint of PFS, the KEYTRUDA combination showed a reduction in the risk of progression of disease or death of 31% compared to sunitinib. In the study, the ORR was 59.3% for patients who received KEYTRUDA in combination with axitinib and 35.7% for those who received sunitinib, with a complete response rate of 5.8% and 1.9% and a partial response rate of 53.5% and 33.8%, for patients receiving the KEYTRUDA combination or sunitinib, respectively. Median duration of response was not reached in the KEYTRUDA combination arm and was 15.2 months in the sunitinib arm. The results for OS, PFS and ORR were consistent across all IMDC risk groups and seen regardless of PD-L1 expression. The observed adverse event profile was as expected based on the known profiles of KEYTRUDA and axitinib. There was a higher incidence of grade 3 or 4 liver enzyme elevation with KEYTRUDA plus axitinib than previously observed with each agent as monotherapy. Merck has filed these data with regulatory authorities worldwide. Merck has an extensive clinical development program in RCC and is advancing multiple potential registration-enabling studies with KEYTRUDA, as monotherapy and in combination with other treatments, including KEYNOTE-564 and KEYNOTE-581.

MRK

Merck

$79.84

0.9 (1.14%)

PFE

Pfizer

$42.41

0.45 (1.07%)

  • 20

    Feb

  • 11

    Apr

  • 18

    May

MRK Merck
$79.84

0.9 (1.14%)

02/14/19
02/14/19
NO CHANGE

Merck initiating three Phase 3 trials with Keytruda for prostate cancer
Merck (announced the presentation of interim data from the Phase 1b/2 KEYNOTE-365 umbrella trial investigating Keytruda, Merck's anti-PD-1 therapy, in combination with various agents for the treatment of patients with metastatic castration-resistant prostate cancer. These early findings show anti-tumor activity across three cohorts of the study, which investigated Keytruda in combination with Lynparza for Cohort A, docetaxel and prednisone for Cohort B, and enzalutamide for Cohort C - with a safety profile consistent with each therapy alone. These results are being presented at the 2019 Genitourinary Cancers Symposium in San Francisco. Based on the findings, Merck is initiating three new pivotal Phase 3 trials with Keytruda in combination with Lynparza, docetaxel and prednisone and enzalutamide. With the initiation of KEYLYNK-010, KEYNOTE-921 and KEYNOTE-641, Merck now has the only program to evaluate overall survival as a co-primary endpoint across three Phase 3 trials.
02/05/19
BOFA
02/05/19
NO CHANGE
BOFA
Merck added to US 1 List, Allergan removed at BofA/Merrill
02/01/19
PIPR
02/01/19
NO CHANGE
Target $3
PIPR
Overweight
Piper says OncoSec's TAVO resensitizing anti-PD-1 progressers 'impressive'
After OncoSec (ONCS) reported updated data for the registrational KEYNOTE-695 study evaluating TAVO plus Merck's (MRK) Keytruda, Piper Jaffray analyst Edward Tenthoff noted that TAVO's ORR improved and called the fact that TAVO resensitized anti-PD-1 progressers "impressive." He reiterates an Overweight and $3 price target on OncoSec shares.
01/23/19
01/23/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Underperform from Sector Perform at RBC Capital with analyst Joseph Spak saying the company's more "tactful messaging" conveys downward pressure to growth expectations and also sees the "realities" of Tesla becoming a volume player highlighting its "challenges to scale and deliver high volume at high ASPs/margins." 2. Lowe's (LOW) downgraded to Hold from Buy at Loop Capital with analyst Laura Champine saying she thinks she was previously too optimistic on Lowe's likely margin progression. 3. Williams-Sonoma (WSM) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman saying he believes top and bottom-line pressures will intensify in 2019. 4. Merck (MRK) downgraded to Market Perform from Outperform at BMO Capital with analyst Alex Arfaei citing the company's over-dependence on Keytruda, the Street's high expectations, and his views on upcoming competitor trials combining for a more balanced risk-reward on Merck. 5. Pfizer (PFE) and Mylan (MYL) were downgraded to Neutral from Buy at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PFE Pfizer
$42.41

0.45 (1.07%)

01/31/19
01/31/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Outperform from Neutral at Credit Suisse and to Buy from Hold at Argus. 2. Tiffany (TIF) upgraded to Overweight from Neutral at Atlantic Equities with analyst Daniela Nedialkova saying the pullback has been largely driven by macro concerns while fundamentals of the brand are strong and preliminary FY19 guidance is conservative. 3. Scotts Miracle-Gro (SMG) upgraded to Neutral from Underweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 4. Geron (GERN) upgraded to Buy from Neutral at B. Riley FBR with analyst George Zavoico saying he believes investors should focus on the pivotal Phase III trial of imetelstat. 5. Ralph Lauren (RL) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Dana Telsey saying the company's improving sakes, combined with ongoing margin expansion, should bolster its earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/31/19
ARGS
01/31/19
UPGRADE
Target $55
ARGS
Pfizer upgraded to Buy from Hold at Argus
Argus analyst David Toung upgraded Pfizer (PFE) to Buy with a price target of $55, saying he anticipates an upward revenue inflection point in 2021 after flat sales in the second half of 2019 and first half of 2020. After cycling through Lyrica loss of exclusivity over the next year, the analyst anticipates Pfizer to benefit from optimized portfolio of assets as it completes its consumer healthcare business joint venture with GlaxoSmithKline (GSK). Toung adds that while he does not "expect major transformational deals", he does see the management pursuing "acquisitions and divestitures that improve long-term profitability".
01/31/19
01/31/19
UPGRADE
Target $47

Outperform
Pfizer upgraded to Outperform on new product story at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Pfizer to Outperform from Neutral and raised his price target on the shares to $47 from $45. The analyst notes that Pfizer has been working through a dark period with extensive patent expirations that have hampered the company's ability to grow, but that period is now nearing an end. Further, the analyst believes the company's new product story with multiple marketed and pipeline assets may be underappreciated.
01/31/19
ARGS
01/31/19
UPGRADE
ARGS
Buy
Pfizer upgraded to Buy from Hold at Argus

TODAY'S FREE FLY STORIES

GRTS

Gritstone Oncology

$11.25

-0.45 (-3.85%)

16:04
03/21/19
03/21
16:04
03/21/19
16:04
Hot Stocks
Gritstone Oncology announces first patient dosed with GRANITE-001 »

Gritstone Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YEXT

Yext

$22.07

-0.07 (-0.32%)

, BHGE

Baker Hughes

$28.51

0.25 (0.88%)

16:04
03/21/19
03/21
16:04
03/21/19
16:04
Hot Stocks
Yext names George Murphy as SVP, Global Strategic Alliances »

Yext (YEXT) has appointed…

YEXT

Yext

$22.07

-0.07 (-0.32%)

BHGE

Baker Hughes

$28.51

0.25 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 28

    May

  • 19

    Mar

OXFD

Oxford Immunotec

$18.00

0.04 (0.22%)

, GE

General Electric

$10.29

0.08 (0.78%)

16:03
03/21/19
03/21
16:03
03/21/19
16:03
Hot Stocks
Oxford Immunotec appoints Matthew McLaughlin CFO »

Oxford Immunotec Global…

OXFD

Oxford Immunotec

$18.00

0.04 (0.22%)

GE

General Electric

$10.29

0.08 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 08

    May

ACGL

Arch Capital

$32.35

0.36 (1.13%)

16:02
03/21/19
03/21
16:02
03/21/19
16:02
Hot Stocks
Arch Capital names John Pasquesi chairman of the board »

Arch Capital Group Ltd.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOK

Nokia

$6.32

0.03 (0.48%)

16:01
03/21/19
03/21
16:01
03/21/19
16:01
Hot Stocks
Nokia reports internal investigation into compliance at Alcatel Lucent »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

BIIB

Biogen

$225.22

-95.25 (-29.72%)

15:59
03/21/19
03/21
15:59
03/21/19
15:59
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

CNC

Centene

$58.93

0.24 (0.41%)

15:55
03/21/19
03/21
15:55
03/21/19
15:55
Options
Centene put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 09

    May

  • 28

    May

NOK

Nokia

$6.30

0.005 (0.08%)

15:52
03/21/19
03/21
15:52
03/21/19
15:52
Periodicals
Finland to investigate Nokia-branded phones over data breach report,Reuters says »

Finland's data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

CAL

Caleres

$25.72

-0.11 (-0.43%)

15:34
03/21/19
03/21
15:34
03/21/19
15:34
Options
Caleres options imply 11.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

CURLF

Curaleaf Holdings

$0.00

(0.00%)

, CVS

CVS Health

$57.28

1.11 (1.98%)

15:28
03/21/19
03/21
15:28
03/21/19
15:28
Hot Stocks
Curaleaf Holdings spikes 22% after report of CBD products pact with CVS »

Shares of Curaleaf…

CURLF

Curaleaf Holdings

$0.00

(0.00%)

CVS

CVS Health

$57.28

1.11 (1.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

LYG

Lloyds Banking

$3.27

-0.115 (-3.40%)

15:27
03/21/19
03/21
15:27
03/21/19
15:27
Options
Puts lead calls 140:1 in Lloyds Banking as shares underperform sector »

Puts lead calls 140:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVZ

Invesco

$19.88

0.16 (0.81%)

15:21
03/21/19
03/21
15:21
03/21/19
15:21
Conference/Events
Invesco management to meet with Morgan Stanley »

Meeting to be held In New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 28

    Mar

BV

BrightView

$15.34

-0.23 (-1.48%)

15:20
03/21/19
03/21
15:20
03/21/19
15:20
Hot Stocks
BrightView under investigation for potential securities laws violations »

Thornton Law Firm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

XHB

SPDR Homebuilders

$38.38

0.82 (2.18%)

15:20
03/21/19
03/21
15:20
03/21/19
15:20
Options
Aggressive call buying in SPDR Homebuilders Fund as the sector sees strength »

Aggressive call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:20
03/21/19
03/21
15:20
03/21/19
15:20
General news
Canada CPI preview »

Canada CPI preview:…

15:20
03/21/19
03/21
15:20
03/21/19
15:20
General news
Canada retail sales preview »

Canada retail sales…

DLAKY

Lufthansa

$0.00

(0.00%)

15:19
03/21/19
03/21
15:19
03/21/19
15:19
Conference/Events
Lufthansa management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

JEF

Jefferies Financial Group

$19.35

0.04 (0.21%)

15:19
03/21/19
03/21
15:19
03/21/19
15:19
Options
Jefferies Financial Group options imply 4.0% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

NEXA

Nexa Resources

$12.46

-0.22 (-1.74%)

15:17
03/21/19
03/21
15:17
03/21/19
15:17
Conference/Events
Nexa Resources management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
03/21/19
03/21
15:17
03/21/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
03/21/19
03/21
15:16
03/21/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
03/21/19
03/21
15:15
03/21/19
15:15
General news
Canada CPI preview »

Canada CPI preview:…

SPY

SPDR S&P 500 ETF Trust

$284.73

3.29 (1.17%)

, SPX

S&P 500

$0.00

(0.00%)

15:14
03/21/19
03/21
15:14
03/21/19
15:14
Periodicals
DoubleLine's Gundlach surprised by Fed's dovish double-down, CNBC says »

DoubleLine Capital CEO…

SPY

SPDR S&P 500 ETF Trust

$284.73

3.29 (1.17%)

SPX

S&P 500

$0.00

(0.00%)

QQQ

Invesco QQQ Trust

$182.53

2.79 (1.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRI

Thomson Reuters

$57.40

0.64 (1.13%)

15:12
03/21/19
03/21
15:12
03/21/19
15:12
Conference/Events
Thomson Reuters management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

15:10
03/21/19
03/21
15:10
03/21/19
15:10
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.